Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment
Breast Cancer Metastatic
DRUG: Ribociclib with fulvestrant|DRUG: Physician's choice treatments group
Progression Free Survival, From the time from randomization to first documented progression or death, whichever occurs first, Up to 5 years
Overall survival, From date of randomization to date of death due to any cause., Up to 5 years|Objective Response Rate, Assessed by RECIST 1.1. Cinical benefit rate defined as percentage of patients with CR, PR per RECIST 1.1 or SD lasting 24 weeks or longer, Up to 5 years|Adverse Events, Incidence/severity of adverse events, lab abnormalities based on CTCAE4.03, Up to 5 years
1. Treatment Arm :

   Ribociclib (600 mg orally once daily on days 1 to 21 in a 28 day cycle) + Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day 15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women) OR,
2. Control Arm (Physician's choice treatments)

   1. Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or periomenopausal women) OR,
   2. Exemestane (25 mg orally once daily on day 1 to 28 in a 28 day cycle) + Everolimus (10 mg orally once daily on day 1 to 28 in a 28 day cycle) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)